The word anaesthesia means ‘loss of sensation’. It can involve a simple local anaesthetic injection which numbs a small part of the body, such as a finger or around a tooth. It can also involve using drugs which cause unconsciousness.
Find out more about Anaesthesia at the NHS websiteROLE_ANONYMOUS
This section of the website is for UK healthcare professionals only. If you are not a healthcare professional, please
click here.
This section of the website is for UK healthcare professionals only. If you are not a healthcare professional, please
click here.
If you are a UK healthcare professional, visit MSD Connect for professional information.
Information for UK members of the public
This website contains information about medicines supplied by MSD in the UK. These medicines are only available on prescription and this website is not intended to replace the advice of a healthcare professional.
You can use this website to find:
- General information about MSD medicines and vaccines
- Information for patients who have been prescribed MSD medicines and vaccines
- Information about diseases and treatments
You should consult your doctor or another suitably trained healthcare professional when considering what type of treatment is most appropriate for you or if you have any questions about medicines prescribed to you.
Want to know more about MSD in the UK? Please visit our corporate page:
Find out about MSDChanges to our trading names and address
Please note that in 2021, MSD will be spinning off products from its women’s health, legacy brands, and biosimilars franchises into a new independent, publicly traded company known as Organon & Co.
Due to legal entity separation in advance of this spin off, we now have two UK registered businesses, MSD and Organon. Organon & Co. is a wholly owned subsidiary of Merck & Co., Inc. of Kenilworth, New Jersey, USA.
As a result of the future spin-off of Organon, as well as our head offices moving to London in early 2021, you will begin to see some changes to references to our products, contact details, materials and statements over the coming months.
Our products are listed alphabetically in groups. You can find out more about our products by using the tabs below to display each group.
You can find out more about some of the diseases and treatment areas we provide medicines for in the list below.
Adempas® (riociguat) 0.5 mg Film-Coated Tablets
Patient Information Leaflet | Summary of Product Characteristics | European Public Assessment Report
Adempas® (riociguat) 1.0 mg Film-Coated Tablets
Patient Information Leaflet | Summary of Product Characteristics | European Public Assessment Report
Adempas® (riociguat) 1.5 mg Film-Coated Tablets
Patient Information Leaflet | Summary of Product Characteristics | European Public Assessment Report
Adempas® (riociguat) 2.0 mg Film-Coated Tablets
Patient Information Leaflet | Summary of Product Characteristics | European Public Assessment Report
Adempas® (riociguat) 2.5 mg Film-Coated Tablets
Patient Information Leaflet | Summary of Product Characteristics | European Public Assessment Report
Arcoxia® (etoricoxib) 30 mg Film-Coated Tablets
Patient Information Leaflet | Summary of Product Characteristics
Arcoxia® (etoricoxib) 60 mg Film-Coated Tablets
Patient Information Leaflet | Summary of Product Characteristics
Arcoxia® (etoricoxib) 90 mg Film-Coated Tablets
Patient Information Leaflet | Summary of Product Characteristics
Arcoxia® (etoricoxib) 120 mg Film-Coated Tablets
Patient Information Leaflet | Summary of Product Characteristics
Asmanex® (mometasone furoate) 200 mcg Twisthaler Inhalation Powder
Patient Information Leaflet | Summary of Product Characteristics
Asmanex® (mometasone furoate) 400 mcg Twisthaler Inhalation Powder
Patient Information Leaflet | Summary of Product Characteristics
Bridion® (sugammadex sodium) 100 mg/ml Solution for Injection
Patient Information Leaflet | Summary of Product Characteristics | European Public Assessment Report
Cancidas® (caspofungin acetate) 50 mg Powder for Concentrate for Solution for Infusion
Patient Information Leaflet | Summary of Product Characteristics | European Public Assessment Report
Cancidas® (caspofungin acetate) 70 mg Powder for Concentrate for Solution for Infusion
Patient Information Leaflet | Summary of Product Characteristics | European Public Assessment Report
Cerazette® (desogestrel) 75 mcg Film-Coated Tablets
Patient Information Leaflet | Summary of Product Characteristics
Cozaar® Comp (losartan potassium/hydrochlorothiazide) 50/12.5 mg Film-Coated Tablets
Patient Information Leaflet | Summary of Product Characteristics
Cozaar® Comp (losartan potassium/hydrochlorothiazide) 100/12.5 mg Film-Coated Tablets
Patient Information Leaflet | Summary of Product Characteristics
Cozaar® Comp (losartan potassium/hydrochlorothiazide) 100/25 mg Film-Coated Tablets
Patient Information Leaflet | Summary of Product Characteristics
Cozaar® (losartan potassium) 12.5 mg Film-Coated Tablets
Patient Information Leaflet | Summary of Product Characteristics
Cozaar® (losartan potassium) 25 mg Film-Coated Tablets
Patient Information Leaflet | Summary of Product Characteristics
Cozaar® (losartan potassium) 50 mg Film-Coated Tablets
Patient Information Leaflet | Summary of Product Characteristics
Cozaar® (losartan potassium) 100 mg Film-Coated Tablets
Patient Information Leaflet | Summary of Product Characteristics
Cubicin® (daptomycin) 350 mg Powder for Solution for Injection or Infusion
Patient Information Leaflet | Summary of Product Characteristics | European Public Assessment Report
Cubicin® (daptomycin) 500 mg Powder for Solution for Injection or Infusion
Patient Information Leaflet | Summary of Product Characteristics | European Public Assessment Report
Delstrigo®▼ (doravirine/lamivudine/tenofovir disoproxil fumarate) 100 mg/300 mg/245 mg Film-Coated Tablets
Patient Information Leaflet | Summary of Product Characteristics | European Public Assessment Report
▼ This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See https://yellowcard.mhra.gov.uk for how to report side effects or search for MHRA Yellow Card in the Google Play or Apple App Store.
Diprosalic® (salicylic acid/betamethasone dipropionate) Ointment
Patient Information Leaflet | Summary of Product Characteristics
Diprosalic® (salicylic acid/betamethasone dipropionate) Scalp Application
Patient Information Leaflet | Summary of Product Characteristics
Diprosone® (betamethasone dipropionate) Cream
Patient Information Leaflet | Summary of Product Characteristics
Diprosone® (betamethasone dipropionate) Lotion
Patient Information Leaflet | Summary of Product Characteristics
Diprosone® (betamethasone dipropionate) Ointment
Patient Information Leaflet | Summary of Product Characteristics
Elocon® (mometasone furoate) Cream
Patient Information Leaflet | Summary of Product Characteristics
Elocon® (mometasone furoate) Ointment
Patient Information Leaflet | Summary of Product Characteristics
Elocon® (mometasone furoate) Scalp Lotion
Patient Information Leaflet | Summary of Product Characteristics
Emend® (aprepitant) 80 mg Hard Capsules
Patient Information Leaflet | Summary of Product Characteristics | European Public Assessment Report
Emend® (aprepitant) 125 mg Hard Capsules
Patient Information Leaflet | Summary of Product Characteristics | European Public Assessment Report
Emend® (aprepitant) 125 mg Powder for Oral Suspension
Patient Information Leaflet | Summary of Product Characteristics | European Public Assessment Report
Esmeron® (rocuronium bromide) 10 mg/ml Solution for Injection
Patient Information Leaflet | Summary of Product Characteristics
Ezetrol® (ezetimibe) 10 mg Tablets
Patient Information Leaflet | Summary of Product Characteristics
Fosamax® (alendronate sodium trihydrate) 70 mg Once Weekly Tablets
Patient Information Leaflet | Summary of Product Characteristics
Fosavance® (alendronate sodium trihydrate/colecalciferol [vitamin D3]) Tablet
Patient Information Leaflet | Summary of Product Characteristics | European Public Assessment Report
Gardasil® (Human Papillomavirus Vaccine [Type 6,11,16,18]) (Recombinant, adsorbed) Suspension for Injection in a Prefilled Syringe or Vial
Patient Information Leaflet | Summary of Product Characteristics | European Public Assessment Report
Gardasil®9 (Human Papillomavirus 9-valent vaccine) (Recombinant, adsorbed) Suspension for Injection in a Prefilled Syringe or Vial
Patient Information Leaflet | Summary of Product Characteristics | European Public Assessment Report
HBVaxPro® (hepatitis B vaccine rDNA) 5 mcg Suspension for Injection in Pre-filled Syringe
Patient Information Leaflet | Summary of Product Characteristics | European Public Assessment Report
HBVaxPro® (hepatitis B vaccine rDNA) 10 mcg Suspension for Injection in Pre-filled Syringe
Patient Information Leaflet | Summary of Product Characteristics | European Public Assessment Report
HBVaxPro® (hepatitis B vaccine rDNA) 40 mcg Suspension for Injection in Pre-filled Syringe
Patient Information Leaflet | Summary of Product Characteristics | European Public Assessment Report
Inegy® (ezetimibe/simvastatin) 10 mg/20 mg Tablets
Patient Information Leaflet | Summary of Product Characteristics
Inegy® (ezetimibe/simvastatin) 10 mg/40 mg Tablets
Patient Information Leaflet | Summary of Product Characteristics
Inegy® (ezetimibe/simvastatin) 10 mg/80 mg Tablets
Patient Information Leaflet | Summary of Product Characteristics
Innovace® (enalapril maleate) 2.5 mg Tablets
Patient Information Leaflet | Summary of Product Characteristics
Innovace® (enalapril maleate) 5 mg Tablets
Patient Information Leaflet | Summary of Product Characteristics
Innovace® (enalapril maleate) 10 mg Tablets
Patient Information Leaflet | Summary of Product Characteristics
Innovace® (enalapril maleate) 20 mg Tablets
Patient Information Leaflet | Summary of Product Characteristics
Innozide® (enalapril maleate/hydrochlorothiazide) 20/12.5 mg Tablets
Patient Information Leaflet | Summary of Product Characteristics
Invanz® (ertapenem sodium) 1 g Powder for Concentrate for Solution for Infusion
Patient Information Leaflet | Summary of Product Characteristics | European Public Assessment Report
Isentress® (raltegravir potassium) 25 mg Chewable Tablets
Patient Information Leaflet | Summary of Product Characteristics | European Public Assessment Report
Isentress® (raltegravir potassium) 100 mg Chewable Tablets
Patient Information Leaflet | Summary of Product Characteristics | European Public Assessment Report
Isentress® (raltegravir potassium) 100 mg Granules for Oral Suspension
Patient Information Leaflet | Summary of Product Characteristics | European Public Assessment Report
Isentress® (raltegravir potassium) 400 mg Film-Coated Tablets
Patient Information Leaflet | Summary of Product Characteristics | European Public Assessment Report
Isentress® (raltegravir potassium) 600 mg Film-Coated Tablets
Patient Information Leaflet | Summary of Product Characteristics | European Public Assessment Report
IVEMEND® (fosaprepitant dimeglumine) 150 mg Powder for Solution for Infusion
Patient Information Leaflet | Summary of Product Characteristics | European Public Assessment Report
Janumet® (sitagliptin phosphate monohydrate/metformin hydrochloride) 50 mg/1,000 mg Film-Coated Tablets
Patient Information Leaflet | Summary of Product Characteristics | European Public Assessment Report
Januvia® (sitagliptin phosphate monohydrate) 25 mg Film-Coated Tablets
Patient Information Leaflet | Summary of Product Characteristics | European Public Assessment Report
Januvia® (sitagliptin phosphate monohydrate) 50 mg Film-Coated Tablets
Patient Information Leaflet | Summary of Product Characteristics | European Public Assessment Report
Januvia® (sitagliptin phosphate monohydrate) 100 mg Film-Coated Tablets
Patient Information Leaflet | Summary of Product Characteristics | European Public Assessment Report
Keytruda® (pembrolizumab) 25 mg/ml Concentrate for Solution for Infusion
Patient Information Leaflet | Summary of Product Characteristics | European Public Assessment Report
NICE | ClinicalTrials.gov
Keytruda® (pembrolizumab) 50 mg Powder for Concentrate for Solution for Infusion
Patient Information Leaflet | Summary of Product Characteristics | European Public Assessment Report
NICE | ClinicalTrials.gov
Further information for patients
Lenvima®▼ (lenvatinib mesilate) 4 mg Hard Capsules
Patient Information Leaflet | Summary of Product Characteristics | European Public Assessment Report
Lenvima®▼ (lenvatinib mesilate) 10 mg Hard Capsules
Patient Information Leaflet | Summary of Product Characteristics | European Public Assessment Report
Marketing Authorisation Holder: Eisai GmbH, Lyoner Straße 36, 60528 Frankfurt am Main, Germany.
▼ This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See https://yellowcard.mhra.gov.uk for how to report side effects or search for MHRA Yellow Card in the Google Play or Apple App Store.
Livial® (tibolone) 2.5 mg Tablets
Patient Information Leaflet | Summary of Product Characteristics
Lotriderm® (betamethasone dipropionate/clotrimazole) Cream
Patient Information Leaflet | Summary of Product Characteristics
Lynparza™(olaparib) 100 mg Film-Coated Tablets
Patient Information Leaflet | Summary of Product Characteristics | European Public Assessment Report
Lynparza™(olaparib) 150 mg Film-Coated Tablets
Patient Information Leaflet | Summary of Product Characteristics | European Public Assessment Report
Lynparza™(olaparib) 50 mg Hard Capsules
Patient Information Leaflet | Summary of Product Characteristics | European Public Assessment Report
Marvelon® (desogestrel/ethinylestradiol) 150/30 mcg Tablets
Patient Information Leaflet | Summary of Product Characteristics
Maxalt Melt® (rizatriptan benzoate) 10 mg Oral Lyophilisates
Patient Information Leaflet | Summary of Product Characteristics
Maxalt® (rizatriptan benzoate) 5 mg Tablets
Patient Information Leaflet | Summary of Product Characteristics
Maxalt® (rizatriptan benzoate) 10 mg Tablets
Patient Information Leaflet | Summary of Product Characteristics
Mercilon® (desogestrel/ethinylestradiol) 150/20 mcg Tablets
Patient Information Leaflet | Summary of Product Characteristics
MMRVaxPro® (measles, mumps and rubella vaccine [live]) Powder and Solvent for Suspension for Injection in Pre-filled Syringe
Patient Information Leaflet | Summary of Product Characteristics | European Public Assessment Report
Moduretic® (hydrochlorothiazide/amiloride hydrochloride) 50 mg/5 mg Tablets
Patient Information Leaflet | Summary of Product Characteristics
Nasonex® (mometasone furoate monohydrate) 50 mcg/actuation Nasal Spray
Patient Information Leaflet | Summary of Product Characteristics
Neoclarityn® (desloratadine) 5 mg Film-Coated Tablets
Patient Information Leaflet | Summary of Product Characteristics | European Public Assessment Report
Neoclarityn® (desloratadine) 0.5 mg/ml Oral Solution
Patient Information Leaflet | Summary of Product Characteristics | European Public Assessment Report
Nexplanon® (etonogestrel) 68 mg Implant for Subdermal Use
Patient Information Leaflet | Summary of Product Characteristics
Noxafil® (posaconazole) 300 mg Concentrate for Solution for Infusion
Patient Information Leaflet | Summary of Product Characteristics | European Public Assessment Report
Noxafil® (posaconazole) 100 mg Gastro-Resistant Tablets
Patient Information Leaflet | Summary of Product Characteristics | European Public Assessment Report
Noxafil® (posaconazole) 40 mg/ml Oral Suspension
Patient Information Leaflet | Summary of Product Characteristics | European Public Assessment Report
Nuvaring® (etonogestrel/ethinylestradiol) Vaginal Delivery System
Patient Information Leaflet | Summary of Product Characteristics
OncoTICE® (2-8 x 108 CFU Tice bacillus calmette-guérin) Powder for Instillation Fluid for Intravesical Use
Patient Information Leaflet | Summary of Product Characteristics
Ontruzant®▼ (trastuzumab) 150 mg Powder for Concentrate for Solution for Infusion
Patient Information Leaflet | Summary of Product Characteristics | European Public Assessment Report
▼ This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See https://yellowcard.mhra.gov.uk for how to report side effects or search for MHRA Yellow Card in the Google Play or Apple App Store.
Pifeltro®▼ (doravirine) 100 mg Film-Coated Tablets
Patient Information Leaflet | Summary of Product Characteristics | European Public Assessment Report
▼ This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See https://yellowcard.mhra.gov.uk for how to report side effects or search for MHRA Yellow Card in the Google Play or Apple App Store.
Pneumococcal polysaccharide vaccine (pneumococcal vaccine polyvalent) Solution for Injection in a Vial
Patient Information Leaflet | Summary of Product Characteristics
Pneumovax® 23 (pneumococcal vaccine polyvalent) Solution for Injection in Pre-filled Syringe
Patient Information Leaflet | Summary of Product Characteristics
Prevymis®▼ (letermovir) 240 mg Film-Coated Tablets
Patient Information Leaflet | Summary of Product Characteristics | European Public Assessment Report
▼ This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See https://yellowcard.mhra.gov.uk for how to report side effects or search for MHRA Yellow Card in the Google Play or Apple App Store.
Primaxin® IV (imipenem monohydrate/cilastatin sodium) 500 mg/500 mg Powder for Solution for Infusion
Patient Information Leaflet | Summary of Product Characteristics
Propecia® (finasteride) 1 mg Film-Coated Tablets
Patient Information Leaflet | Summary of Product Characteristics
Proscar® (finasteride) 5 mg Film-Coated Tablets
Patient Information Leaflet | Summary of Product Characteristics
Rebetol® (ribavirin) 40 mg/ml Oral Solution
Patient Information Leaflet | Summary of Product Characteristics | European Public Assessment Report
Remicade® (infliximab) 100 mg Powder for Concentrate for Solution for Infusion
Patient Information Leaflet | Summary of Product Characteristics | European Public Assessment Report
Further information for patients
Restandol® Testocaps™ (testosterone undecanoate) 40 mg Soft Capsules
Patient Information Leaflet | Summary of Product Characteristics
Simponi® (golimumab) 50 mg Solution for Injection in Pre-Filled Pen
Patient Information Leaflet | Summary of Product Characteristics | European Public Assessment Report
Further information for patients
Simponi® (golimumab) 50 mg Solution for Injection in Pre-Filled Syringe
Patient Information Leaflet | Summary of Product Characteristics | European Public Assessment Report
Further information for patients
Simponi® (golimumab) 100 mg Solution for Injection in Pre-Filled Pen
Patient Information Leaflet | Summary of Product Characteristics | European Public Assessment Report
Further information for patients
Half Sinemet CR (carbidopa/levodopa) 25 mg/100 mg Prolonged-Release Tablets
Patient Information Leaflet | Summary of Product Characteristics
Sinemet® (carbidopa/levodopa) 12.5 mg/50 mg Tablets
Patient Information Leaflet | Summary of Product Characteristics
Sinemet® (carbidopa/levodopa) 10 mg/100 mg Tablets
Patient Information Leaflet | Summary of Product Characteristics
Sinemet® (carbidopa/levodopa) 25 mg/250 mg Tablets
Patient Information Leaflet | Summary of Product Characteristics
Sinemet® CR (carbidopa/levodopa) 50 mg/200 mg Prolonged-Release Tablets
Patient Information Leaflet | Summary of Product Characteristics
Sinemet Plus (carbidopa/levodopa) 25 mg/100 mg Tablets
Patient Information Leaflet | Summary of Product Characteristics
Singulair® (montelukast sodium) 10 mg Tablets
Patient Information Leaflet | Summary of Product Characteristics
Singulair® Paediatric (montelukast sodium) 4 mg Chewable Tablets
Patient Information Leaflet | Summary of Product Characteristics
Singulair® Paediatric (montelukast sodium) 5 mg Chewable Tablets
Patient Information Leaflet | Summary of Product Characteristics
Singulair® Paediatric (montelukast sodium) 4 mg Granules
Patient Information Leaflet | Summary of Product Characteristics
Sivextro®(tedizolid phosphate) 200 mg Film-Coated Tablets
Patient Information Leaflet | Summary of Product Characteristics | European Public Assessment Report
Sivextro®(tedizolid phosphate) 200 mg Powder for Concentrate for Solution for Infusion
Patient Information Leaflet | Summary of Product Characteristics | European Public Assessment Report
Steglatro®▼(ertugliflozin L-pyroglutamic acid) 5 mg Film-Coated Tablets
Patient Information Leaflet | Summary of Product Characteristics | European Public Assessment Report
Steglatro®▼(ertugliflozin L-pyroglutamic acid) 15 mg Film-Coated Tablets
Patient Information Leaflet | Summary of Product Characteristics | European Public Assessment Report
▼ This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See https://yellowcard.mhra.gov.uk for how to report side effects or search for MHRA Yellow Card in the Google Play or Apple App Store.
Sycrest®(asenapine) 5 mg Sublingual Tablets
Patient Information Leaflet | Summary of Product Characteristics
Sycrest®(asenapine) 10 mg Sublingual Tablets
Patient Information Leaflet | Summary of Product Characteristics
Temodal® (temozolomide) 5 mg/20 mg/100 mg/140 mg/180 mg/250 mg Hard Capsules
Patient Information Leaflet | Summary of Product Characteristics | European Public Assessment Report
VAQTA® Adult (hepatitis A vaccine, inactivated, adsorbed) Suspension for Injection in a Prefilled Syringe or Vial
Patient Information Leaflet | Summary of Product Characteristics
VAQTA® Paediatric (hepatitis A vaccine, inactivated, adsorbed) Suspension for Injection in a Prefilled Syringe or Vial
Patient Information Leaflet | Summary of Product Characteristics
Varivax® (varicella virus vaccine [live]) Powder and Solvent for Suspension for Injection
Patient Information Leaflet | Summary of Product Characteristics
Zepatier®▼(elbasvir/grazoprevir) 50 mg/100 mg Film-Coated Tablets
Patient Information Leaflet | Summary of Product Characteristics | European Public Assessment Report
▼ This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See https://yellowcard.mhra.gov.uk for how to report side effects or search for MHRA Yellow Card in the Google Play or Apple App Store.
Zerbaxa® (ceftolozane sulfate/tazobactam sodium) 1 g/0.5 g Powder for Concentrate for Solution for Infusion
Patient Information Leaflet | Summary of Product Characteristics | European Public Assessment Report
Zinplava®▼(bezlotoxumab) 25 mg/ml Concentrate for Solution for Infusion
Patient Information Leaflet | Summary of Product Characteristics | European Public Assessment Report
▼ This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See https://yellowcard.mhra.gov.uk for how to report side effects or search for MHRA Yellow Card in the Google Play or Apple App Store.
Zocor® (simvastatin) 10 mg Film-Coated Tablets
Patient Information Leaflet | Summary of Product Characteristics
Zocor® (simvastatin) 20 mg Film-Coated Tablets
Patient Information Leaflet | Summary of Product Characteristics
Zocor® (simvastatin) 40 mg Film-Coated Tablets
Patient Information Leaflet | Summary of Product Characteristics
Zocor® (simvastatin) 80 mg Film-Coated Tablets
Patient Information Leaflet | Summary of Product Characteristics
Zostavax® (shingles [herpes zoster] vaccine [live]) Powder and Solvent for Suspension for Injection
Patient Information Leaflet | Summary of Product Characteristics | European Public Assessment Report
GB-NON-03496 | Date of Preparation: November 2020
